Login to Your Account

Financings Roundup

Ariad Pads Cash with $300M For Iclusig Launch, Clinic Work

By Jennifer Boggs
Managing Editor

Friday, January 25, 2013
A month after the earlier-than-expected approval of Iclusig (ponatinib) in chronic myelogenous leukemia (CML), Ariad Pharmaceuticals Inc. is taking advantage of the current public markets to more than double its cash balance.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription